About the SARS-CoV-2 vaccine

Home  »  Research and monitoring of COVID-19  »  About the SARS-CoV-2 vaccine
Print version

Press release on the development at the FBUN NIIEM named after academician I.N. Blokhina

Rospotrebnadzor of a prototype vaccine against

novel coronavirus / norovirus infections

As part of the Rospotrebnadzor Sectoral Research Program, the institute is conducting research on obtaining a combined candidate mucosal vaccine for the prevention of new coronavirus and norovirus infections. Recombinant norovirus VP1 protein obtained by the authors using a norovirus isolate circulating in the Russian Federation is used as a universal technological platform for constructing various antigenic compositions in the composition of virus-like particles.

It is assumed that the vaccine under development will be applicable to prevent new coronavirus and norovirus infections in people of different age groups, primarily in children and the elderly, including in the form of intranasal administration in the form of a spray / drops.

A laboratory test of one of the prototype vaccine variants is currently underway.